New lupus injection enters first human tests
NCT ID NCT06144710
First seen Mar 28, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This early-stage trial tests a new drug called SG301, given as an injection under the skin every two weeks, for systemic lupus erythematosus (SLE). The study first gives a single dose to healthy volunteers to check safety, then gives multiple doses to people with lupus. The main goal is to see if the drug is safe and how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
-
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, 200040, China
-
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, 330006, China
-
Jining First People's Hospital
Jining, Shandong, 272002, China
-
Pingxiang People's Hospital
Pingxiang, Jiangxi, 337099, China
-
Shandong University Qilu Hospital
Jinan, Shandong, 250063, China
-
Shenzhen People's Hospital
Shenzhen, Guangdong, 518020, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233000, China
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350004, China
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 314408, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SG301 injection (a drug given under the skin every two weeks)
What this could lead to
If it works, this could point toward a new treatment option for systemic lupus erythematosus (SLE).
What could go wrong
This is a very early Phase 1 trial with only 48 participants, so it is primarily testing safety and dosing. It is too soon to know if the drug will actually help lupus symptoms.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.